Skip to content
OpenCapital
Get started

C4 Therapeutics CCCC Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$6.2MBeat by $1.8MDiluted EPS-$0.20Beat by $0.05
Revenue estimate$4.4M
EPS estimate-$0.25

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$8.2M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$6.2MBeat by $1.8M
Q4 2025$11.0MBeat by $5.6MQ3 2025$11.2MBeat by $6.8MQ2 2025$6.5MMiss by $337.0KQ1 2025$7.2MBeat by $3.7MQ4 2024$5.2MBeat by $1.8M

Diluted EPS

Q1 2026-$0.20Beat by $0.05
Q4 2025-$0.18Beat by $0.13Q3 2025-$0.44Beat by $0.03Q2 2025-$0.37Beat by $0.01Q1 2025-$0.37Beat by $0.11Q4 2024-$0.49Miss by $0.05

Ask the moment C4 Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did C4 Therapeutics report Q1 2026 earnings?
C4 Therapeutics (CCCC) reported Q1 2026 earnings on May 12, 2026 before market open.
What were C4 Therapeutics's Q1 2026 revenue and EPS?
C4 Therapeutics reported revenue of $6.2M and diluted EPS of $-0.20 for Q1 2026.
Did C4 Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $4.4M by $1.8M. EPS beat the consensus estimate of $-0.25 by $0.05.
How did C4 Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 14.3% from $7.2M a year earlier and diluted EPS grew 45.9% from $-0.37.
Where can I find C4 Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-033861) and the 10-Q periodic report (0001628280-26-033865) directly on SEC EDGAR. The filing index links above go to sec.gov.